These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 9414892)

  • 21. Cadaveric renal transplantation against a positive historic crossmatch under tacrolimus immunosuppression: long-term follow-up.
    Lyne JC; Vivas CA; Shapiro R; Scantlebury VP; Hakala TR; Starzl TE; Jordan ML
    Transplant Proc; 1997; 29(1-2):312. PubMed ID: 9123015
    [No Abstract]   [Full Text] [Related]  

  • 22. Predicting factors for long-term results of OKT3 therapy in steroid-resistant acute rejection following cadaveric renal transplantation.
    Rostaing L; Chabannier MH; Modesto A; Rouzaud A; Cisterne JM; Tkaczuk J; Durand D
    Transplant Proc; 1998 Jun; 30(4):1170-2. PubMed ID: 9636473
    [No Abstract]   [Full Text] [Related]  

  • 23. Treatment of steroid resistant rejection following renal transplantation: benefits and risks of OKT3 therapy.
    Kehinde EO; Feehally J; Scriven SD; Veitch PS; Bell PR
    Transplant Proc; 1996 Jun; 28(3):1449-50. PubMed ID: 8658735
    [No Abstract]   [Full Text] [Related]  

  • 24. Delayed graft function of cadaveric renal transplants is prevented by diltiazem.
    Carmellini M; Salvadori M; Di Stefano R; Bertoni E; Nicita G; Rosati A; Taddei G; Rindi P; Rizzo G; Mosca F
    Transplant Proc; 1996 Feb; 28(1):80-2. PubMed ID: 8644348
    [No Abstract]   [Full Text] [Related]  

  • 25. Impact of improving immunosuppressive treatment on outcome in cadaveric kidney transplantation.
    Knechtle SJ; Heisey DM; Pirsch JD; D'Alessandro AM; Kalayoglu M; Sollinger HW
    Surgery; 1996 Oct; 120(4):719-24. PubMed ID: 8862383
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Consequences of anti-OKT3 antibody development: OKT3 reuse and long-term graft survival.
    Shield CF
    Transplant Proc; 1993 Apr; 25(2 Suppl 1):81-2. PubMed ID: 8465434
    [No Abstract]   [Full Text] [Related]  

  • 27. Cytomegalovirus prophylaxis in pediatric renal transplant recipients.
    So S; Mayo C; McCullough C; Jendrisak M; Woodle S; Marsh W; Bailey T
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1414-5. PubMed ID: 8382865
    [No Abstract]   [Full Text] [Related]  

  • 28. Ganciclovir prophylaxis of cytomegalovirus disease.
    Conti DJ; Shen G; Singh T; Isenberg A; Freed BM
    Transplant Proc; 1997; 29(1-2):804-6. PubMed ID: 9123534
    [No Abstract]   [Full Text] [Related]  

  • 29. Tailoring immunosuppressive therapy based on donor and recipient risk factors.
    First MR
    Transplant Proc; 2001 May; 33(3):2207-11. PubMed ID: 11377504
    [No Abstract]   [Full Text] [Related]  

  • 30. Impact of OKT3 treatment for steroid resistant rejection of renal allografts: the long-term outcome at a single center.
    Inui M; Tanabe K; Ishikawa N; Tokumoto T; Harano M; Otsubo S; Suzuki K; Goya N; Yagisawa T; Nakazawa H; Fuchinoue S; Toma H
    Transplant Proc; 1999 Nov; 31(7):2870-1. PubMed ID: 10578320
    [No Abstract]   [Full Text] [Related]  

  • 31. Antibody therapy in steroid-resistant rejection.
    Waiser J; Budde K; Schreiber M; Böhler T; Löbermann LA; Neumayer HH
    Transplant Proc; 1998 Aug; 30(5):1778-9. PubMed ID: 9723279
    [No Abstract]   [Full Text] [Related]  

  • 32. Human donor bone marrow cells can enhance hyporeactivity in renal transplantation using maintenance FK 506 and OKT3 induction therapy.
    Ciancio G; Carreno M; Mathew J; Ricordi C; Garcia R; Karatzas T; Fuller L; Cirocco R; Burke G; Webb M; Nery J; Tzakis A; Roth D; Esquenazi V; Miller J
    Transplant Proc; 1996 Apr; 28(2):943-4. PubMed ID: 8623473
    [No Abstract]   [Full Text] [Related]  

  • 33. Renal transplantation in children less than six years old.
    Garcia CD; Barros V; Schneider L; Guimarães P; Didone E; Guerra EE; Vitola SP; Garcia VD
    Transplant Proc; 2001; 33(7-8):3595-6. PubMed ID: 11750527
    [No Abstract]   [Full Text] [Related]  

  • 34. Treatment of cytomegalovirus infections with gancyclovir during OKT3 administration.
    Haberal M; Velidedoğlu E; Arslan G; Bilgin N; Büyükpamukçu N; Karamehmetoğlu M
    Transplant Proc; 1995 Oct; 27(5):2707. PubMed ID: 7482883
    [No Abstract]   [Full Text] [Related]  

  • 35. Comparison between three different antilymphocyte induction protocols in renal transplant recipients with delayed graft function.
    Sumrani N; Hong JH; DiBenedetto A; Clayton R; Miles AM; Markell MS; Distant DA; Fleishhacker J; Sommer BG
    Transplant Proc; 1996 Feb; 28(1):400-1. PubMed ID: 8644289
    [No Abstract]   [Full Text] [Related]  

  • 36. Preventive OKT3 treatment with cyclosporine (Sandimmun) for second kidney transplantation.
    Perner F; Alföldy F; Járay J; Hidvégi M; Hemangshu P
    Transpl Int; 1994; 7 Suppl 1():S255-8. PubMed ID: 11271218
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A drug of the past, a lesson for the future.
    Vincenti F
    Pediatr Transplant; 2005 Jun; 9(3):267-8. PubMed ID: 15910379
    [No Abstract]   [Full Text] [Related]  

  • 38. Mycophenolate mofetil immunosuppressive therapies increase the incidence of cytomegalovirus infection in renal transplantation.
    Munoz MA; Andrés A; Gallego R; Morales E; Morales JM; Aguado JM; Lumbreras C; Torres A; Rodicio JL; Praga M
    Transplant Proc; 2002 Feb; 34(1):97. PubMed ID: 11959202
    [No Abstract]   [Full Text] [Related]  

  • 39. OKT3 for primary therapy of the first rejection episode in kidney transplants.
    Tesi RJ; Elkhammas EA; Henry ML; Ferguson RM
    Transplantation; 1993 May; 55(5):1023-9. PubMed ID: 8497875
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A prospective randomized trial of OKT3 vs ATGAM induction therapy in pancreas transplant recipients.
    Stratta RJ; Taylor RJ; Weide LG; Sindhi R; Sudan D; Castaldo P; Cushing KA; Frisbie K; Radio SJ
    Transplant Proc; 1996 Apr; 28(2):917-8. PubMed ID: 8623461
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.